Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis
Abstract
Compared with placebo, 35%-40% more patients receiving a full induction course of vedolizumab had sustained clinical remission after 52 weeks of therapy. This result was observed irrespective of TNF antagonist treatment history. Clinical remission at week 14 may therefore be a predictor for sustaine …
Keywords
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
humans
pubmed abstract
nih
national institutes of health
national library of medicine
prognosis
research support
non-u.s. gov't
adult
female
male
Remission Induction
Antibodies
Monoclonal
follow-up studies
pmid:30365009
PMC6499937
doi:10.1093/ibd/izy323
Brian G Feagan
Stefan Schreiber
Sharon O'Byrne
Humanized / therapeutic use*
Colitis
Ulcerative / drug therapy*
Gastrointestinal Agents / therapeutic use*
Induction Chemotherapy*
Severity of Illness Index*
Citation
ID:
110503
References
Blockchain Verification
Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
110503
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Loading...
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
Creates 1,000,000 NFT tokens for this article
Token Features:
- ERC-1155 Standard NFT
- 1 Million Supply per Article
- Transferable via MetaMask
- Permanent Blockchain Record
Scan with Saymatik Web3.0 Wallet